Peer Reviewed Publications

2017

BRUUN TH, GRASSMANN V, ZIMMER B, ASBACH B, PETERHOFF D, KLICHE A, WAGNER R. (2017) Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins. MAbs. 2017 Aug 17; Epub ahead of print; [abstract]

JOSEPH S, QUINN K, GREENWOOD A, COPE AV, MCKAY PF, HAYES PJ, KOPYCINSKI JT, GILMOUR J, MILLER AN, GELDMACHER C, NADAI Y, AHMED MI, MONTEFIORI DC, DALLY L, BOULIOTIS G, LEWIS DJ, TATOUD R, WAGNER R, ESTEBAN M, SHATTOCK RJ, MCCORMACK S, WEBER J. (2017) A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes. Front Immunol. 2017 Feb 22;8:149. [abstract]

BARABAS S, SPINDLER T, KIENER R, TONAR C, LUGNER T, BATZILLA J, BENDFELDT H, RASCLE A, ASBACH B, WAGNER R, DEML L. (2017) An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity. BMC Immunol. 2017 Mar 7;18(1):14. [abstract]

BANAS B, BÖGER CA, LÜCKHOFF G, KRÜGER B, BARABAS S, BATZILLA J, SCHEMMERER M,, KÖSTLER J, BENDFELDT H, RASCLE A, WAGNER R, DEML L, LEICHT J, KRÄMER BK. (2017) Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients. BMC Immunol. 2017 Mar 7;18(1):15. [abstract]

ASBACH B, WAGNER R. (2017) Particle-based delivery of the HIV envelope protein. Curr Opin HIV AIDS. 2017 May;12(3):265-271 [abstract] (Review)

PETERHOFF D, WAGNER R. (2017) Guiding the long way to broad HIV neutralization. Curr Opin HIV AIDS. 2017 May;12(3):257-264 [abstract] (Review)

GARCÍA-ARRIAZA J, PERDIGUERO B, HEENEY JL, SEAMAN MS, MONTEFIORI DC, YATES NL, TOMARAS GD, FERRARI G, FOULDS KE, ROEDERER M, SELF SG, BORATE B, GOTTARDO R, PHOGAT S, TARTAGLIA J, BARNETT SW, BURKE B, CRISTILLO AD, WEISS DE, LEE C, KIBLER KV, JACOBS BL, WAGNER R, DING S, PANTALEO G, ESTEBAN M. (2017) HIV/AIDS vaccine candidates based on replication-competent recombinant poxvirus NYVAC-C-KC expressing trimeric gp140 and Gag-derived VLPs or lacking the viral molecule B19 that inhibits type I interferon activate relevant HIV-1-specific B and T cell immune functions in non-human primates. J Virol. 2017 Feb 8. pii: JVI.02182-16; Epub ahead of print [abstract]

2016

ZURAWSKI G, ZURAWSKI S, FLAMAR AL, RICHERT L, WAGNER R, TOMARAS GD, MONTEFIORI DC, ROEDERER M, FERRARI G, LACABARATZ C, BONNABAU H, KLUCAR P, WANG Z, FOULDS K, KAO SF, YATES N, LABRANCHE C, JACOBS B, KIBLER B, ASBACH B, KLICHE A, SALAZAR A, REED S, SELF S, GOTTARDO R, GALMIN L, WEISS D, CRISTILLO C, THIEBAUT R, PANTALEO G, LEVY Y. (2016) Targeting HIV-1 Env Gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. PLoS One. 2016 Apr 14;11(4):e015348 [abstract]

ASBACH B, KLICHE A, KÖSTLER J, PERDIGUERO B, ESTEBAN M, JACOBS BL, MONTEFIORI DC, LABRANCHE CC, YATES NL, TOMARAS GD, FERRARI G, FOULDS KE, ROEDERER M, LANDUCCI G, FORTHAL DN, SEAMAN MS, HAWKINS N, SELF SG, SATO A, GOTTARDO R, PHOGAT S, TARTAGLIA J, BARNETT SW, BURKE B, CRISTILLO AD, WEISS DE, FRANCIS J, GALMIN L, DING S, HEENEY JL, PANTALEO G, WAGNER R. (2016) Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. J Virol. 2016 Mar 28;90(8):4133-49 [abstract]

2015

KRINNER S, HEITZER A, ASBACH B, WAGNER R. (2015) Interplay of promoter usage and intragenic CpG content: Impact on GFP reporter gene expression. Hum Gene Ther. 2015 Dec;26(12):826-40. Epub 2015 Sep 29. [abstract]

GARCÍA-ARRIAZA J, PERDIGUERO B, HEENEY J, SEAMAN M, MONTEFIORI DC, LABRANCHE C, YATES NL, SHEN X, TOMARAS GD, FERRARI G, FOULDS KE, MCDERMOTT A, KAO SF, ROEDERER M, HAWKINS N, SELF S, YAO J, FARRELL P, PHOGAT S, TARTAGLIA J, BARNETT SW, BURKE B, CRISTILLO A, WEISS D, LEE C, KIBLER K, JACOBS B, ASBACH B, WAGNER R, DING S, PANTALEO G, ESTEBAN M. (2015) Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime/boost combination with Env protein in non-human primates. J. Virol. 2015 Aug;89(16):8525-39. Epub 2015 Jun 3. [abstract]

PATEL P, ASBACH B, SHTEYN E, GOMEZ C, COLTOFF A, BHUYAN S, TYNER AL, WAGNER R, BLAIN SW. (2015) Brk/PTK6 phosphorylates p27Kip1, regulating the activity of cyclin D-CDK4. Mol Cell Biol. 2015 May;35(9):1506-22. Epub 2015 Mar 2. [abstract]

MOOIJ P, KOOPMAN G, DRIJFHOUT JW, NIEUWENHUIS IG, BEENHAKKER N, KOESTLER J, BOGERS WM, WAGNER R, ESTEBAN M, PANTALEO G, HEENEY JL, JACOBS BL, MELIEF CJ. (2015) Synthetic long peptide booster immunization in rhesus macaques primed with replication competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1. J Gen Virol. 2015 Jun;96(Pt 6):1478-1483. Epub 2015 Feb 9. [abstract]

PERDIGUERO B, GÓMEZ CE, CEPEDA V, SÁNCHEZ-SAMPEDRO L, GARCÍA-ARRIAZA J, MEJÍAS-PÉREZ E, JIMÉNEZ V, SÁNCHEZ C, SORZANO CO, OLIVEROS JC, DELALOYE J, ROGER T, CALANDRA T, ASBACH B, WAGNER R, KIBLER KV, JACOBS BL, PANTALEO G, ESTEBAN M. (2015) Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as VLPs. J Virol. 2015 Jan 15;89(2):970-88. [abstract]

2014

MCCOY LE, RUTTEN L, FRAMPTON D, ANDERSON I, GRANGER L, BASHFORD-ROGERS R, DEKKERS G, STROKAPPE NM, SEAMAN MS, KOH W, GRIPPO V, KLICHE A, VERRIPS T, KELLAM P, FASSATI A, WEISS RA. (2014) Molecular evolution of broadly neutralizing llama antibodies to the CD4-binding site of HIV-1. PLoS Pathog. 2014 Dec 18;10(12):e1004552. [abstract]

BRUUN TH, MÜHLBAUER K, BENEN T, KLICHE A, WAGNER R. (2014) A Mammalian Cell Based FACS-Panning Platform for the Selection of HIV-1 Envelopes for Vaccine Development. PLoS One. 2014 Oct 3;9(10):e109196. [abstract]

BENEN TD, TONKS P, KLICHE A, KAPZAN R, HEENEY JL, WAGNER R. (2014) Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein. J Biomed Sci. 2014 Aug 27;21(1):79. [abstract]

LAI RPJ, HOCK M, RADZIMANOWSKI J, TONKS P, HULSIK DJ, EFFANTIN G, SEILLY DJ, DREJA H, KLICHE A, WAGNER R, BARNETT SW, TUMBA N, MORRIS L, LABRANCHE CC, MONTEFIORI DC, SEAMAN MS, HEENEY JL, WEISSENHORN W. J Biol Chem. (2014) A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. 2014 Oct 24;289(43):29912-26 [abstract]

KRINNER S, HEITZER AP, DIERMEIER SD, OBERMEIER I, LÄNGST G, WAGNER R. (2014) CpG domains downstream of TSSs promote high levels of gene expression. Nucleic Acid Res. 2014 Apr;42(6):3551-64. [abstract]

2013

KOOPMAN G, BEENHAKKER N, NIEUWENHUIS I, DOXIADIS G, MOOIJ P, DRIJFHOUT JW, KOESTLER J, HANKE T, FAGROUCH Z, VERSCHOOR EJ, BONTROP RE, WAGNER R, BOGERS WM, MELIEF CJ. (2013) DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. AIDS. 2013 Nov 28;27(18):2841-51 [abstract]

2012

Liss M, Daubert D, Brunner K, Kliche K, Hammes U, Leiherer A, Wagner R. (2012) Embedding permanent watermarks in synthetic genes. PLoS One. 2012;7(8):e42465. [abstract]

ASBACH B, LUDWIG C, SAKSELA K, WAGNER R. (2012) Comprehensive Analysis of Interactions between the Src-Associated Protein in Mitosis of 68 kDa and the Human Src-Homology 3 Proteome. PLoS One. 2012;7(6):e38540. [abstract]

TENBUSCH M, IGNATIUS R, NCHINDA G, TRUMPFHELLER C, SALAZAR AM, TÖPFER K, SAUERMANN U, WAGNER R, HANNAMAN D, TENNER-RACZ K, RACZ P, STAHL-HENNIG C, UBERLA K. (2012) Immunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaques. PLoS One. 2012;7(6):e39038. [abstract]

JUNGLAS B, KUESPERT S, SELEEM AA, STRULLER T, ULLMANN S, BÖSL M, BOSSERHOFF A, KÖSTLER J, WAGNER R, TAMM ER, FUCHSHOFER R. (2012) Connective Tissue Growth Factor Causes Glaucoma by Modifying the Actin Cytoskeleton of the Trabecular Meshwork. Am J Pathol. 2012 Jun;180(6):2386-403. [abstract]

GÓMEZ CE, PERDIGUERO B, JIMÉNEZ V, FILALI-MOUHIM A, GHNEIM K, HADDAD EK, QUAKKERLAAR ED, DELALOYE J, HARARI A, ROGER T, DUNHEN T, SÉKALY RP, MELIEF CJ, CALANDRA T, SALLUSTO F, LANZAVECCHIA A, WAGNER R, PANTALEO G, ESTEBAN M. (2012) Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C. PLoS One. 2012;7(4):e35485. [abstract]

BÖCKL K, WILD J, BREDL S, KINDSMÜLLER K, KÖSTLER J, WAGNER R. (2012) Altering an Artificial Gagpolnef Polyprotein and Mode of ENV Co-Administration Affects the Immunogenicity of a Clade C HIV DNA Vaccine. PLoS One. 2012;7(4):e34723. [abstract]

NOTKA F, WAGNER R. (2012) Reprogramming a GFP Reporter Gene Subjects It to Complex Lentiviral Gene Regulation. Methods Mol Biol. 2012;813:85-106. [abstract]

2011

FREISCHMIDT A, LISS M, WAGNER R, KALBITZER HR, HORN G. (2011) RNA secondary structure and in vitro translation efficiency. Protein Expr Purif. 2012 Mar;82(1):26-31; [abstract]

KIBLER KV, GOMEZ CE, PERDIGUERO B, WONG S, HUYNH T, HOLECHEK S, ARNDT W, JIMENEZ V, GONZALEZ-SANZ R, DENZLER K, HADDAD EK, WAGNER R, SÉKALY RP, TARTAGLIA J, PANTALEO G, JACOBS BL, ESTEBAN M. (2011) Improved NYVAC-Based Vaccine Vectors. PLoS One., 6(11):e25674; [abstract]

AGWALE SM, FORBI JC, NOTKA F, WRIN T, WILD J, WAGNER R, WOLF H. (2011) Broad Antibody Mediated Cross-Neutralization and Preclinical Immunogenicity of New Codon-Optimized HIV-1 Clade CRF02_AG and G Primary Isolates. PLoS One., 6(8):e23233; [abstract]

PERREAU M, WELLES HC, HARARI A, HALL O, MARTIN R, MAILLARD M, DORTA G, BART PA, KREMER EJ, TARTAGLIA J, WAGNER R, ESTEBAN M, LEVY Y, PANTALEO G. (2011) DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell responses in Intestinal Mucosa. J Virol., 85(19):9854-62; [abstract]

NOTKA F, LISS M, WAGNER R. (2011) Industrial scale gene synthesis. Methods Enzymol., 498:247-75; [abstract]

FLYNN BJ, KASTENMÜLLER K, WILLE-REECE U, TOMARAS GD, ALAM M, LINDSAY RW, SALAZAR AM, PERDIGUERO B, GOMEZ CE, WAGNER R, ESTEBAN M, PARK CG, TRUMPFHELLER C, KELER T, PANTALEO G, STEINMAN RM, SEDER R. (2011) Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci USA, 108(17):7131-6; [abstract]

FATH S, BAUER AP, LISS M, SPRIESTERSBACH A, MAERTENS B, HAHN P, LUDWIG C, SCHÄFER F, GRAF M, WAGNER R. (2011) Multiparameter RNA and Codon Optimization: A Standardized Tool to Assess and Enhance Autologous Mammalian Gene Expression. PLOS One, 6(3):e17596; [abstract]

2010

KOSOVAC D, WILD J, LUDWIG C, MEISSNER S, BAUER AP, WAGNER R. (2010) Minimal doses of a sequence-optimized transgene mediate high level and longterm EPO expression in vivo: challenging CpG-free gene design. Gene Ther., 18(2):189-98. [abstract]

ASBACH B, KOLB M, LISS M, WAGNER R, SCHÄFERLING M. (2010) Protein Microarray Assay for the Screening of SH3 Domain Interactions. Anal Bioanal Chem., 398(5):1937-46; [abstract]

HOFMANN-SIEBER H, WILD J, FIEDLER N, TISCHER K, VON EINEM J, OSTERRIEDER N, HOFMANN H, KÖSTLER J, WAGNER R. (2010) Impact of ETIF Deletion on Safety and Immunogenicity of EHV-1 Vectored Vaccines. J Virol., 84(22):11602-13; [abstract]

RAAB D, GRAF M, NOTKA F, SCHÖDL T, WAGNER R. (2010) The GeneOptimizer Algorithm: Using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization. Syst Synth Biol., 4(3):215-25; [abstract]

FREISCHMIDT A, MEYSING M, LISS M, WAGNER R, KALBITZER HR, HORN G. (2010) Limiting factors of the translation machinery. J Biotechnol., 150(1):44-50; [abstract]

MAERTENS B, SPRIESTERSBACH A, VON GROLL U, ROTH U, KUBICEK J, GERRITS M, GRAF M, LISS M, DAUBERT D, WAGNER R, SCHÄFER F. (2010) Gene optimization mechanisms: A multi-gene study reveals a high success rate of full-length human proteins expressed in Escherichia coli. Protein Sci., 19(7):1312-1326; [abstract]

BAUER AP, LEIKAM D, KRINNER S, NOTKA F, LUDWIG C, LÄNGST G, WAGNER R. (2010) The impact of intragenic CpG content on gene expression. Nucleic Acids Res., 38(12):3891-908; [abstract]

GACH JS, FURTMÜLLER PG, QUENDLER H, MESSNER P, WAGNER R, KATINGER H, KUNERT R. (2010) Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1. J. Biol. Chem., 285(2):1122-7; [abstract]

2009

MGC PROJECT TEAM, TEMPLE G, GERHARD DS, RASOOLY R, FEINGOLD EA, GOOD PJ, ROBINSON C, MANDICH A, DERGE JG, LEWIS J, SHOAF D, COLLINS FS, JANG W, WAGNER L, SHENMEN CM, MISQUITTA L, SCHAEFER CF, BUETOW KH, BONNER TI, YANKIE L, WARD M, PHAN L, ASTASHYN A, BROWN G, FARRELL C, HART J, LANDRUM M, MAIDAK BL, MURPHY M, MURPHY T, RAJPUT B, RIDDICK L, WEBB D, WEBER J, WU W, PRUITT KD, MAGLOTT D, SIEPEL A, BREJOVA B, DIEKHANS M, HARTE R, BAERTSCH R, KENT J, HAUSSLER D, BRENT M, LANGTON L, COMSTOCK CL, STEVENS M, WEI C, VAN BAREN MJ, SALEHI-ASHTIANI K, MURRAY RR, GHAMSARI L, MELLO E, LIN C, PENNACCHIO C, SCHREIBER K, SHAPIRO N, MARSH A, PARDES E, MOORE T, LEBEAU A, MURATET M, SIMMONS B, KLOSKE D, SIEJA S, HUDSON J, SETHUPATHY P, BROWNSTEIN M, BHAT N, LAZAR J, JACOB H, GRUBER CE, SMITH MR, MCPHERSON J, GARCIA AM, GUNARATNE PH, WU J, MUZNY D, GIBBS RA, YOUNG AC, BOUFFARD GG, BLAKESLEY RW, MULLIKIN J, GREEN ED, DICKSON MC, RODRIGUEZ AC, GRIMWOOD J, SCHMUTZ J, MYERS RM, HIRST M, ZENG T, TSE K, MOKSA M, DENG M, MA K, MAH D, PANG J, TAYLOR G, CHUAH E, DENG A, FICHTER K, GO A, LEE S, WANG J, GRIFFITH M, MORIN R, MOORE RA, MAYO M, MUNRO S, WAGNER S, JONES SJ, HOLT RA, MARRA MA, LU S, YANG S, HARTIGAN J, GRAF M, WAGNER R, LETOVKSY S, PULIDO JC, ROBISON K, ESPOSITO D, HARTLEY J, WALL VE, HOPKINS RF, OHARA O, WIEMANN S. (2009) The completion of the Mammalian Gene Collection (MGC). Genome Res. 2009 Dec;19(12):2324-33; [abstract]

WILD J, BIELER K, KÖSTLER J, FRACHETTE MJ, JEFFS S, VIEIRA S, ESTEBAN M, LILJESTRÖM P, PANTALEO G, WOLF H, WAGNER R. (2009) Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral Immunol. 22(5):309-19; [abstract]

LEIHERER A, LUDWIG C, WAGNER R. (2009) Uncoupling HIV-1 gag and pol reading frames: Role of the transframe protein p6* in viral replication. J. Virol.,83(14):7210-20; [abstract]

MOOIJ P, BALLA-JHAGJHOORSINGH SS, BEENHAKKER N, VAN HAAFTEN P, BAAK I, NIEUWENHUIS IG, HEIDARI S, WOLF H, FRACHETTE MJ, BIELER K, SHEPPARD N, HARARI A, BART PA, LILJESTRÖM P, WAGNER R, PANTALEO G, HEENEY JL. (2009) Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding HIV-1 clade C immunogens. J. Virol., 83(11):5881-9; [abstract]

LEIHERER A, LUDWIG C, WAGNER R. (2009) Influence of extended mutations of the HIV-1 transframe protein p6 on Nef-dependent viral replication and infectivity in vitro. Virology, 387(1):200-10; [abstract]

2008

KREUTER A, POTTHOFF A, BROCKMEYER NH, GAMBICHLER T, STÜCKER M, ALTMEYER P, SWOBODA J, PFISTER H, WIELAND U; GERMAN COMPETENCE NETWORK HIV/AIDS (Collaborator: WAGNER R). (2008) Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. J Invest Dermatol, 128(8):2078-83; [abstract]

SPETH C, BREDL S, HAGLEITNER M, WILD J, DIERICH M, WOLF H, SCHROEDER J, WAGNER R, DEML L. (2008) Human immunodeficiency virus type-1 (HIV-1) Pr55(gag) virus-like particles are potent activators of human monocytes. Virology, 382(1):46-58; [abstract]

BART PA, GOODALL R, BARBER T, HARARI A, GUIMARAES-WALKER A, KHONKARLY M, SHEPPERD N,  BANGALA Y, FRACHETTE MJ, WAGNER R, LILJESTROM P, KRAHENBUHL JP, GIRARD M, GOUDSCHMIDT J, ESTEBAN M, HEENEY J, SATTENTAU Q, MCCORMACK S, BABIKER A, PANTALEO G, WEBER J. (2008) EV01: A Phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 13;26(25):3153-61; [abstract]

MCCORMACK S, STÖHR W, BARBER T, BART PA, HARARI A, MOOG CH, CIUFFREDA D, CELLERAI CH, COWEN M, GAMBONI R, BURNET S, LEGG K, BRODNICKI E, WOLF H, WAGNER R, HEENEY J, FRACHETTE MJ, TARTAGLIA J, BABIKER A, PANTALEO G, WEBER J. (2008) EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 13;26(25):3162-74; [abstract]

VERSTREPEN BE, BINS AD, ROLLIER CS, MOOIJ P, KOOPMAN G, SHEPPARD NC, SATTENTAU Q, WAGNER R, WOLF H, SCHUMACHER TN, HEENEY JL, HAANEN JB. (2008) Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine 26(26):3346-51; [abstract]

HAMMER D, WILD J, LUDWIG C, ASBACH B, NOTKA F, WAGNER R. (2008) Fusion of EBNA1-Derived Gly-Ala Repeat to Transdominant HIV-1 Gag Increases Inhibitory Activities and Survival of Transduced Cells In Vivo. Hum Gene Ther 19(6):622-34; [abstract]

STOLTE-LEEB N, BIELER K, KÖSTLER J, HEENEY J, TEN HAAFT P, SUH Y, HUNSMANN G, STAHL-HENNIG C, WAGNER R. (2008) Better Protective Effects in Rhesus Macaques by Combining Systemic and Mucosal Application of a Dual Component Vector Vaccine After Rectal SHIV89.6P Challenge Compared to Systemic Vaccination Alone. Viral Immunol 21(2):235-46; [abstract]

LUDWIG C, LEIHERER A, WAGNER R. (2008) Importance of protease cleavage sites within and flanking HIV-1 transframe protein p6* for spatiotemporal regulation of protease activation. J Virol 82(9):4573-84; [abstract]

CORBETT M, BOGERS W, HEENEY JL, GERBER S, GENIN C, DIDIERLAURENT A, OOSTERMEIJER H, DUBBES R, BRASKAMP G, LERONDEL S, GOMEZ CE, ESTEBAN M, WAGNER R, KONDOVA I, MOOIJ P, BALLA-JHAGJHOORSINGH J, BEENHAKKER N, KOOPMAN G, VAN DER BURG S, KRAEHENBUHL JP, LE PAPE A. (2008) Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci USA 105(6):2046-51; [abstract]

HARARI A, BART PA, STÖHR W, TAPIA G, GARCIA M, MEDJITNA-RAIS E, BURNET S, CELLERAI C, ERLWEIN O, BARBER T, MOOG C, LILJESTROM P, WAGNER R, WOLF H, KRAEHENBUHL JP, ESTEBAN M, HEENEY J, FRACHETTE MJ, TARTAGLIA J, MCCORMACK S, BABIKER A, WEBER J, PANTALEO G. (2008) An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205(1):63-77; [abstract]

MOOIJ P, BALLA-JHAGJHOORSINGH SS, KOOPMAN G, BEENHAKKER N, VAN HAAFTEN P, BAAK I, NIEUWENHUIS I, KONDOVA I, WAGNER R, WOLF H, GÓMEZ CE, NÁJERA JL, JIMÉNEZ V, ESTEBAN M, HEENEY JL. (2008) Differential CD4+ versus CD8+ T-cell responses elicited by different Poxvirus-based HIV-1 vaccine candidates provide comparable efficacy in primates. J Virol 82(6):2975-88; [abstract]

GOLDWICH A, HAHN SSC, SCHREIBER S, MEIER S, KÄMPGEN E, WAGNER R, LUTZ M, SCHUBERT U. (2008) Targeting HIV-1 Gag into the Defective Ribosomal Product Pathway Enhances MHC Class I Antigen Presentation and CD8+ T Cell Activation. J Immunol 180(1):372-82; [abstract]

2007

HEIKKINEN LS, KAZLAUSKAS A, MELEN K, WAGNER R, ZIEGLER T, JULKUNEN I, SAKSELA K. (2007) Avian and 1918 Spanish influenza A virus NS1 proteins bind to Crk/CrkL SH3 domains to activate host cell signalling. JBC 29;283(9):5719-27; [abstract]

HARARI A, CELLERAI C, BELLUTTI ENDERS F, KÖSTLER J, CODARRI L, TAPIA G, BOYMAN O, CASTRO E, GAUDIERI S, JAMES I, JOHN M, WAGNER R, MALLAL S, PANTALEO G. (2007) Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. PNAS 104(41):16233-8; [abstract]

BÜGL H, DANNER JP, MOLINARI RJ, MULLIGAN JT, PARK H-O, REICHERT B, ROTH DA, WAGNER R, BUDOWLE B, SCRIPP RM, SMITH JAL, STEELE SJ, CHURCH G, ENDY D (2007) DNA synthesis and biological security. Nat Biotechnol 25(6):627-629; [abstract]

KESTI T, RUPPELT A, WANG J-H, LISS M, WAGNER R, KJETIL T, SAKSELA K (2007) Reciprocal regulation of SH3 and SH2 domain binding via tyrosine phosphorylation of a common site in CD3e. J Immunol 179(2):878-85; [abstract]

LARKE N, IM EJ, WAGNER R, WILLIAMSON C, WILLIAMSON AL, McMICHAEL AJ, HANKE T (2007) Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur J Immunol. 37(2):566-77 [abstract]

LESCHONSKY B, LUDWIG C, BIELER K, WAGNER R (2007) Capsid stability and replication of human immunodeficiency virus I are influenced critically by charge and size of Gag residue 183. J Gen Virol 88:207-16; [abstract]

GOMEZ CE, NAJERA JL, JIMENEZ V, BIELER K, WILD J, KOSTIC L, HEIDARE S, CHEN M, FRACHETTE MJ, PANTALEO G, WOLF H, LILJESTROEM P, WAGNER R, ESTEBAN M (2007) Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25:1969-92; [abstract]

GOMEZ CE, NAJERA JL, PEREZ JIMENEZ E, JIMENEZ V, WAGNER R, GRAF M, FRACHETTE MJ, LILJESTROEM P, PANTALEO G, ESTEBAN M (2007) Head-to-head comparision of the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1 BX08 gp120 and HIV-1 IIIB Gag-Pol-Nef proteins of clade B. Vaccine 25:2863-85 [abstract]

2006

GRAF M, LUDWIG C, KEHLENBECK S, JUNGERT K, WAGNER R (2006) A quasi-lentiviral green fluorescent protein reporter exhibits nuclear export features of late human immunodeficiency virus type 1 transcripts. Virology 352(2):295-305; [abstract]

KUATE S, STAHL-HENNIG C, STOIBER H, NCHINDA G, FLOTO A, FRANZ M, SAUERMANN U, BREDL S, DEML L, IGNATIUS R, NORLEY S, RACZ P, TENNER-RACZ K, STEINMAN RM, WAGNER R, ÜBERLA K (2006) Immunogenicity and Efficacy of Immunodeficiency Virus-Like Particles Pseudotyped with the G protein of Vesicular Stomatitis Virus. Virology 351(1):133-44; [abstract]

KARKKAINEN S, HIIPAKKA M, WANG JH, KLEINO I, VAHA-JAAKKOLA M, RENKEMA GH, LISS M, WAGNER R, SAKSELA K (2006) Identification of preferred protein interactions by phage-display of the human Src homology-3 proteome. EMBO 7(2):186-91; [abstract]

2005

SIGERT S, THALERT S, WAGNER R, SCHNIERLE BS (2005) Assessment of HIV-1 entry inhibitors by MLV/HIV-1 pseudotyped vectors. AIDS Res Ther 12;2-7; [abstract]

KOOPMAN G, MORTIER D, NIPHUIS H, FARESE AM, KAHN LE, MANN D, WAGNER R, MACVITTIE TJ, WOULFE SL, HEENEY JL (2005) Systemic mobilization of antigen presenting cells, with a chimeric Flt-3 and G-CSF receptor agonist, during immunization of Macaca mulatta with HIV-1 antigens is insufficient to modulate immune responses or vaccine efficacy. Vaccine 23(33):4195-202; [abstract]

TRAPP S, von EINEM J, HOFMANN H, KÖSTLER J, WILD J, WAGNER R, BEER M, OSTERRIEDER N (2005) Potential of Equine Herpesvirus 1 as a vector for immunization. J Virol 79:5445-5454; [abstract]

2004

PAULUS C, LUDWIG C, WAGNER R (2004) Contribution of the Gag-Pol transframe domain p6* and its coding sequence to morphogenesis and replication of human immunodeficiency virus type 1. Virology 330:271-83; [abstract]

NOTKA F, MEIER G, WAGNER R (2004) Concerted inhibitory activities of Phyllanthus amarus on HIV replication in vitro and ex vivo. Antiviral Res 64:93-102; [abstract]

DIDIERLAURENT A, RAMIREZ JC, GHERARDI M, ZIMMERLI SC, GRAF M, ORBEA HA, PANTALEO G, WAGNER R, ESTEBAN M, KRAEHENBUHL JP, SIRARD JC (2004) Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine 22:3395-403; [abstract]

WILD J, BOJAK A, DEML L, WAGNER R (2004) Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model. Vaccine 22:1732-43; [abstract]

MOOIJ P, NIEUWENHUIS IG, KNOOP CJ, DOMS RW, BOGERS WM, TEN HAAFT PJ, NIPHUIS H, KOORNSTRA W, BIELER K, KÖSTLER J, MOREIN B, CAFARO A, ENSOLI B, WAGNER R, HEENEY JL (2004) Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection. J Virol 78:3333-42; [abstract]

GRUNWALD T, PEDERSEN FS, WAGNER R, UBERLA K (2004) Reducing mobilization of simian immunodeficiency virus based vectors by primer complementation. J Gene Med (2):147-54; [abstract]

2003

DEML L, WILD J, WAGNER R (2003) Virus-like particles: a novel tool for the induction and monitoring of both T-helper and cytotoxic T-lymphocyte activity. Methods Mol Med 94:133-57; [abstract]

GRAF M, DEML L, WAGNER R (2003) Codon-optimized genes that enable increased heterologous expression in mammalian cells and elicit efficient immune responses in mice after vaccination of naked DNA. Methods Mol Med 94:197-210; [abstract]

WILD J, WAGNER R (2003) Status and current strategies of HIV vaccine development. Internist (Berl) 44:711-8; [abstract]

KOFMAN A, GRAF M, DEML L, KHARAZOVA A, WOLF H, WAGNER R (2003) Co-influence of transgene expression in mammalian cells. Mutual influence of transgenes on their expression in mammalian cells. Tsitologiia (4):387-91; [abstract]

KOFMAN A, GRAF M, BOJAK A, DEML L, BIELER K, KHARAZOVA A, WOLF H, WAGNER R (2003) HIV-1 gag expression is quantitatively dependent on the ratio of native and optimized codons. Tsitologiia (1):86-93; [abstract]

NOTKA F, MEIER GR, WAGNER R (2003) Inhibition of wild-type human immunodeficiency virus and reverse transcriptase inhibitor-resistant variants by Phyllanthus amarus. Antiviral Res. 58:175-86; [abstract]

2002

BOJAK A, WILD J, DEML L, WAGNER R (2002). Impact of Codon Usage Modification on T Cell Immunogenicity and Longevity of HIV-1 Gag-Specific DNA Vaccines. Intervirology 45: 275-286; [abstract]

LOTTI B, WENDLAND T, FURRER H, YAWALKAR N, VON GREYERZ S, SCHNYDER K, BRANDES M, VERNAZZA P, WAGNER R, NGUYEN T, ROSENBERG E, PICHLER WJ, BRANDER C (2002). Cytotoxic HIV-1 p55gag-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines.
J Clin Immunol 22(5):253-62; [abstract]

INDRACCULO S, HABELER W, STIEVANO L, PIOVAN E, WAGNER R, ÜBERLA K, CHIECO-BIANCHI L, AMADORI A (2002). Gene transfer in ovarian cancer cells: A comparison between retroviral and lentiviral vectors. Cancer Research. Cancer Research 62:6099-107; [abstract]

KUATE S, WAGNER R, ÜBERLA K (2002) Development and characterization of a minimal inducible packaging cell line for simian immunodeficiency virus-based lentiviral vectors. J. Gene. Med. 4:347-55; [abstract]

HEINTEL T, SESTER M, BARTOLOMÉ RODRÍGUEZ M, KRIEG C, SESTER U, WAGNER R, PEES H, GÄRTNER B, MAIER R,  MEYERHANS A (2002) The fraction of perforin-expressing HIV-specific CD8 T cells is a marker for disease progression in HIV infection. AIDS 16:1497-501; [abstract]

BOJAK A, WILD J, WOLF H, WAGNER R (2002) Efficiency of a myogenic DNA vaccine is strictly dependent upon cellular localization of HIV-1 Pr55gag. Vaccine. 20:1980-1984; [abstract]

BOJAK A, HAMMER D, WOLF H, WAGNER R (2002) Muscle specific versus ubiquitous expression of Gag based HIV-1 vaccines: a comparative analysis. Vaccine 20:1975-1979; [abstract]

2001

DEML L, BOJAK A, STECK S, GRAF M, WILD J, SCHIRMBECK R, WOLF H, WAGNER R (2001) Multiple effects of codon usage optimization on the expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 (HIV-1) Gag protein. J.Virol. 75:10991-11001; [abstract]

BUONAGURO L, BUONAGURO F, TOMESELLO M, MANTAS D, BETH-GIRALDO E, WAGNER R, MICHELSON S, PREVOST M, WOLF H, GIRALDO G (2001) High efficient production of Pr55gag virus-like particles expressing multiple HIV-epitopes including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res. 49:35-47; [abstract]

2000

WAGNER R, GRAF M, BIELER K, WOLF H, GRUNWALD T, FOLEY P, ÜBERLA K (2000) Rev-independent expression of synthetic gag-pol genes of HIV-1 and SIV:Implications for the safety of lentiviral vectors. Human Gene Therapy 11:2403-13; [abstract]

SESTER M, SESTER U, KÖHLER H, SCHNEIDER T, DEML L, PEES H, WAGNER R, MEYERHANS A (2000) Rapid whole blood analysis of antigen specific CD4+ and CD8+ T-cell responses against protein immunogens in vitro: Application for the analysis of persistent HIV infection. AIDS 14:2653-2650; [abstract]

PIYASIRISILP S, MCCUTCHAN FE, CARR JK, SANDERS-BUELL E, CHEN J, WAGNER R, WOLF H, SHAO Y, LAI S, BEYRER C, YU XF (2000) A recent outbreak of human immunodeficiency virus type 1 infection in southern china was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol. 74:11286-95; [abstract]

GRAF M, BOJAK A, DEML L, WOLF H, WAGNER R (2000) Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression. J. Virol. 74:10822-10826; [abstract]

SU L, GRAF M, VON BRIESEN H, XING H, KÖSTLER J, MELZL H, WOLF H, SHAO Y, WAGNER R (2000) Cloning and characterization of virtually full-length HIV genome of a prevalent intersubtype (C/B') recombinant strain in China. J. Virol. 74:11367-11376; [abstract]

PALIARD X, LIU Y, WAGNER R, WOLF H, BAENZINGER J, WALKER CM (2000) Priming of strong, broad and long-lived HIV-1p55gag -specific CTL following administration of a virus-like particle vaccine in rhesus macaques. AIDS Research and Human Retroviruses 3:273-282; [abstract]

1999
FITZON T, LESCHONSKY B, PAULUS C, WOLF H, WAGNER R (1999) The NH2-terminal core domain of the HIV-1 p24 capsid mojety is involved in early steps of the viral life cycle. Virology 268:294-307

NOTKA F, STAHL-HENNIG C, DITTMER U, WOLF H, WAGNER R (1999) Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on the induction of neutralizing antibodies. Vaccine 18:291-301

PAULUS C, HELLEBRAND S, TEESMER U, WOLF H, KRÄUßLICH HG, WAGNER R (1999) Competitive inhibition of the HIV-1 protease by the viral transframe protein p6*. Journal of Biological Chemistry 274:21539-21543

DEML L, SCHIRMBECK R, REIMANN J, WOLF H, WAGNER R (1999) Purification and characterization of hepatitis B virus surface antigen particles produced in Drosophila Schneider-2 insect cells. J. Virol. Methods 79:205-217

DEML L, WOLF H, WAGNER R (1999) High level expression of Hepatitis-B-Virus surface antigen in stable transfected Drosophila Schneider-2 cells. J. Virol. Methods 79:191-103

DEML L, SCHIRMBECK R, REIMANN J, WOLF H, WAGNER R (1999) Immunostimulatory CpG motifs trigger a T-helper 1 immune response to human immunodeficiency virus type 1 (HIV-1) gp160 envelope proteins. Clin. Chem. 37:199-204

HEENEY J, AKERBLOM L, BARNETT S, BOGERS W, BRUCK C, DAVID D, FULLER D, KOOPMAN G, LEHNER, T, MOOIJ P, MOREIN B, MORGHEN C, ROSENWIRTH B, VERSCHOOR E, VOSS G, WAGNER R, WOLF H (1999) HIV-1 vaccine induced immune responses which correlate with protection from SHIV infection. Immunology letters 66:189-195

NOTKA F, STAHL-HENNIG C, DITTMER U, WOLF H, WAGNER R (1999) Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model. Biol. Chem. 380:341-352

WAGNER R, SHAO Y, WOLF H (1999) Correlates of protection, antigen delivery and molecular epidemiology: Basics for designing an HIV vaccine. Vaccine 17:1706-1710

WAGNER R, LESCHONSKY B, HARRER E, PAULUS C, WEBER C, WALKER BD, BUCHBINDER S, WOLF H, KALDEN JR, HARRER T (1999) Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized by CTL from a long term non progressor: Constrains on the immune escape by targeting an epitope essentially involved in viral replication. J. Immunol. 162:3727-34

1998
HARRER T, HARRER E, BARBOSA P, KAUFMANN F, WAGNER R, BRÜGGEMANN S, KALDEN JR, FEINBERG M, JOHNSON RO, BUCHBINDER S, WALKER BD (1998) Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term non-progressing HIV-1 infected individual. J. Immunol. 161: 4875-4881

BUONAGURO L, BUONAGURO FM, RUSSO F, TORNESELLO ML, BETH-GIRALDO E, WOLF H, WAGNER R, GIRALDO G (1998) Biomolecular characterization of a novel gp120 coding sequence from an Ugandan HIV-1 isolate of the A clade containing a large sequence insertion in the V4 major variable region. Aids Res. Hum Retroviruses 14:1287-1289

WAGNER R, TEEUWSEN VJ, DEML L, NOTKA F, HAAKSMA AGM, JHAGJHOORSINGH SS, NIPHIUS H, WOLF H, HEENEY JH (1998) Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV-1 vaccines in the absence of protection from SHIV infection. Virology 245: 65-74.

GRAF M, SHAO Y, Zhao Q, SEIDL T, WOLF H, WAGNER R (1998) Cloning and characterization of an almost full length molecular clone of a Thai subtype B' virus strain isolated from an asymptomatic intravenous drug abuser south of china. Aids Res. Hum. Retroviruses 14:285-288

1997 
DEML L, KRATOCHWIL G, OSTERRIEDER N, KNÜCHEL R, WOLF H, WAGNER R (1997) Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into pr55gag virus-like particles by an Epstein Barr virus gp220/350 derived transmembrane domain. Virology 235:10-25

DEML L, SCHIRMBECK R, REIMANN J, WOLF H, WAGNER R (1997) Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytolytic T-cells and neutralizing antibodies. Virology 235:26-39

1996
BEISINGER M, PAULUS C, BEIER P, WOLF H, RÖSCH P, WAGNER R (1996) Sequence specific resonance assignments of the 1H-NMR spectra and structural characterization in solution of the HIV-1 transframe protein p6* purified under native conditions. European J. Biochemistry 237:383-392

WAGNER R, DEML L, NOTKA F, WOLF H, SCHIRMBECK R, REIMANN J, TEEUWSEN V, HEENEY J (1996). Safety and immunogenicity of recombinant HIV-1 particles in rodents and rhesus Macaques. Intervirology 39:93-104

WAGNER R, DEML L, SCHIRMBECK R, NIEDRIG M, REIMANN J, WOLF H (1996) Construction, expression and immunogenicity of chimeric HIV-1 virus-like particles. Virology 220:128-140

WAGNER R, DEML L, TEEUWSEN V, HEENEY J, YIMING S, WOLF H (1996) A recombinant HIV-1 virus-like particle vaccine: From concepts to a field study. Antibiot. Chemother. 48:68-83

1995
SCHIRMBECK R, DEML L, MELBER K, WOLF H, WAGNER R, REIMANN J (1995) Priming of Class I-restricted cytotoxic T-lymphocytes by vaccination with recombinant protein antigens without adjuvants. Vaccine 13:857-865

OSTERRIEDER K, WAGNER R, BRANDMÜLLER C, SCHMIDT P, WOLF H, KAADEN OR (1995) Protection against EHV-1 Challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology. 208:500-510

BORBE H, STUBER G, WAGNER R, WOLF H, MODROW S (1995) Structural and immunological reactivity of the principle neutralizing determinant V3 of gp120/HIV-1. Journal of Peptide Science 1:109-123

1994
WAGNER R, DEML L, WOLF H (1994) Polyvalent, recombinant HIV-virus-like particles: Novel HIV vaccine strategies. Antibiot Chemother 46:48-61

MODROW S, KATTENBECK B, VON POBLOTZKI A, NIEDRIG M, WAGNER R, WOLF H (1994) The gag proteins of human immunodeficiency virus type 1: mechanisms of virus assembly and possibilities for interference. Medical Microbiology and Immunology 183:177-194

OSTERRIEDER K, WAGNER R, PFEFFER M, KAADEN O (1994) Expression of glycoprotein gp14 of equine herpesvirus I (EHV-I) in E. Coli and in insect cells: A comparative study on protein processing and human immune response. J. Gen. Virol. 75:2041-2046

WAGNER R, DEML L, FLIEßBACH H, WANNER G, WOLF H (1994) Assembly and extracellular release of chimeric Pr55gag retrovirus-like particles. Virology 200:162-175

1993
BAVAND MR, WAGNER R, RICHMOND TJ (1993) HIV-1 reverse transcriptase: Polymerization properties of the p51 homodimer compared to the p66/p51 heterodimer. Biochemistry 32:10543-10552

POBLOTZKI A, WAGNER R, WANNER G, NIEDRIG M, WOLF H, MODROW S (1993) Identification of a region in the Pr55gag-polyprotein essential for HIV-1 particle formation. Virology 193: 981-985

WAGNER R, BÖLTZ T, DEML, L, MODROW S, WOLF H (1993) Induction of cytolytic T-lyphocytes directed towards the V3-loop of the HIV-1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses. J. Gen. Virol. 74:1261-1269

1992  
WAGNER R, MODROW S, BÖLTZ T, FLIEßBACH H, NIEDRIG M, V. BRUNN A, WOLF H (1992) Immunological reactivity of a human immunodeficiency virus type 1 derived peptide representing a consensus sequence of the gp120 major neutralizing region V3. Arch. Virol. 127:139-152

WAGNER R, FLIEßBACH H, WANNER G, MOTZ M, NIEDRIG M, DEBY G, V. BRUNN A, WOLF H (1992) Studies on processing, particle formation and immunogenicity of the HIV-1 gag-gene product: A possible component of a HIV vaccine. Arch. Virol. 127:117-137

Patent Applications

2000
WAGNER R, GRAF M (2000) Kernexportreportersysteme. Priority 30.10.00, DE 100 53 781.2; PCT, pending

WAGNER R, GRAF M, DEML L, BIELER K (2000) Synthetic GagPol genes and their uses. European Patent Application. Priority 18.05.00. EP 00110623.6; PCT; pending

1999
WAGNER R, WOLF H, GRAF M, SHAO Y (1999) HIV-1 Intersubtype (C/B') genome and uses thereof. German Patent Application, Priority 16.11.99., DE 199 55 089.1; PCT, pending

1995
WAGNER R, DEML L, OSTERRIEDER K, NOTKA F, WOLF H (1995) Antigen presentation system based on retrovirus-like particles that allow the presentation of complete or composite proteins to the immune system. European Patent Application. Priority: EP/31.03.95

1990 
WAGNER R, V.BRUNN A, MODROW S, WOLF H (1990) Subregion of the retroviral env protein, DNA sequences encoding it and compositions for the diagnosis, prevention or therapy of retrovirus infections. European Patent Application. Priority: EP/21.3.90/ EP90105313; Application No. 91104433.7

WAGNER R, FLIEßBACH H, V.BRUNN A, MOTZ M, WOLF H (1990) DNA sequences encoding modified retroviral gag polypeptides and vaccines containing them or aggregates thereof. European Patent Application. Priority: EP/21.03.90/ EP 90105319. Application No. 91104432; erteilt

English Reviews And Book Articles

2008
GRAF M, SCHOEDL T, WAGNER R (2009) Rationales of Gene Design and De Novo Gene Construction. In: Systems Biology and Synthetic Biology, eds. Fu P, Latterich M, Panke S. Wiley-Interscience, ISBN 0471767786, Chapter 12:407-434

2007
LUDWIG C, WAGNER R (2007) Virus-like Particles - Universal Molecular Toolboxes. Curr Opin Biotechnol 18(6):537-45; [abstract]

2005
DEML L, SPETH C, DIERICH MP, WOLF H, WAGNER R (2005) Recombinant HIV-1 Pr55(gag) virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 42:259-277; [abstract]

2003
DEML L, WILD J, WAGNER R (2003) Virus-like particles: a novel tool for the induction and monitoring of both T-helper and cytotoxic T-lymphocyte activity. Methods Mol Med 94:133-57; [abstract]

GRAF M, DEML L, WAGNER R (2003) Codon-optimized genes that enable increased heterologous expression in mammalian cells and elicit efficient immune responses in mice after vaccination of naked DNA. Methods Mol Med 94:197-210; [abstract]

2002
BOJAK A, DEML L, WAGNER R (2002) Past, present and future of HIV-vaccine development: A critical view. Drug Discovery Today. 7:18-28; [abstract]

2001  
WAGNER R, Graf M (2001) Improved safety and efficiency profiles of lentiviral vectors and DNA vaccines by synthetic genes. BioTech International. 13:20-21

BIELER K, WAGNER R (2001) Synthetic genes for prevention and therapy: Implications on safety and efficacy of DNA vaccines and lentiviral Vectors. in: Plasmids for Therapy and Vaccination. ed. Martin Schleef. Wiley-VCH. ISBN 3.527-30269-7. Chapter 9:147-168

1998
LESCHONSKY B, DEML L, NOTKA F, GRAF M, WOLF H, WAGNER R (1998) Learning from long-term non-progressing HIV infected individuals for HIV vaccine design. Italian Biochemical Society Transactions. 11:118-122

DEML L, GRAF M, LESCHONSKY B, BOJAK A, BIELER K, SU L, WOLF H, WAGNER R (1998) Strategies to improve the efficacy of particulate HIV-1 subunit vaccines for future field studies. (Polly Roy and Claude Leclerc eds.). Proceedings of EC Biotechnology and Vaccinology. 2:89-92

WOLF H, NOTKA F, DEML L, LESCHONSKY B, WALKER B, HARRER T, WAGNER R (1998) Role of the gag-specific cytotoxic T-lymphozytes during HIV-pathogenesis: Implications for the development of virus-like particle based HIV vaccines. in: Retroviruses of human AIDS and related animal diseases. (Marc Girard, Betty Dodet, eds) Colloque Des Cent Gardes. 179-185

1996
DEML L, WOLF H, WAGNER R (1996) Recombinant Drosophila Schneider -2 cells as a novel tool to produce recombinant antigens for diagnostic, therapeutic and preventive purposes. in: Molecular Biology-Based Methods in Clinical Diagnosis. (Reischl, U. ed.). The Humana Press Inc. 11:185-199

1995 
WAGNER R, DEML L, FITZON T, WOLF H (1995) HIV morphogenesis: Target for antiviral therapy and basis for the development of a rationally designed candidate vaccine. (Chanock, R.M., Ginsberg, H.S., Brown, F., Lerner, R.A., eds). Modern approaches to new vaccines including prevention of AIDS. CSH Laboratory press. Vaccines. 347-356

WAGNER R, DEML L, SCHIRMBECK R, REIMANN J, WOLF H (1995) Induction of a MHC class I restricted, CD8 positive cytotoxic T cell response by chimeric HIV-1 virus-like particles in vivo: Implications on HIV vaccine development. Modern Vaccine Design, (F.R. Seiler and G. Schulz eds), Behring Communications. 95:23-34

WAGNER R, WOLF H (1995) New concepts in HIV-vaccine development. The Microbiologist. 6:4-12

1994
WOLF H, MODROW S, WAGNER R (1994) The HIV-1 Pr55gag Protein: Understanding the mechanism of virus assembly as a basis for the development of novel therapeutics and vaccines. in: Retroviruses of human AIDS and related animal diseases. (Marc Girard, Louis Valette, eds) Colloque Des Cent Gardes. 299-307

DEML L, ROßHUBER S, WOLF H, WAGNER R (1994) High level expression and characterization of hepatitis B-virus surface antigen in stable transfected Drosophila Schneider 2 cells. BioForum 32-35

1993
WAGNER R, BÖLTZ T, KOSZINOWSKI U, NIEDRIG M, MODROW S, WOLF H (1993) Immunological reactivity of a consensus sequence of the HIV-1 principal neutralizing determinant V3. Peptides. 1993. (Schneider C.H. and Eberle A.N. eds), ESCOM Science Publishers, B.V. 900-902

NIEDRIG M, BICKHARD H, GELDERBLOM H, PAULI G, MODROW S, V. POBLOTZKI A, WAGNER R, WOLF H (1993) Assembly of HIV-gag proteins: A target for antiviral therapy? (Chanock, R.M., Ginsberg, H.S., Brown, F., Lerner, R.A., eds). Modern approaches to new vaccines including prevention of AIDS. CSH Laboratory press. Vaccines. 93: 209-214

BORBE H, WAGNER R, STUBER G, HABAZETTL J, HOLAK TA, WOLF  H, MODROW S (1993) The V3-loop of gp120/HIV-1: Structural, functional and immunological characterization. Peptides. 1992. (Schneider C.H. and Eberle A.N. eds), 1993 ESCOM Science Publishers, B.V. 571-572

MODROW S, V. POBLOTZKI A, WAGNER R, GELDERBLOM A, PAULI G, WOLF H, NIEDRIG M (1993) Assembly of HIV-1 gag-proteins: A new target for antiviral peptide therapy? Peptides. 1992. (Schneider C.H. and Eberle A.N. eds), 1993 ESCOM Science Publishers, B.V.  133-135

1992 
WAGNER R (1992) Review on: Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved HIV type I sequences; published by Shafferman et al., PNAS, USA 88:7126-7130. 1992. AIDS-Forschung 6:316-317

1991
WAGNER R, FLIEßBACH H, MODROW S, BÖLTZ T, GELDERBLOM H, V. BRUNN A, WOLF H (1991) Expression of HIV-1 autologous p55- and p55/gp120-V3 core particles: a new approach in HIV vaccine developement. (Chanock, R.M., Ginsberg, H.S., Brown, F., Lerner, R.A., eds). Modern approaches to new vaccines including prevention of AIDS. CSH Laboratory Press. Vaccines 91: 109-111

German Reviews And Book Articles

2013

WAGNER R, ASBACH B. (2013) Immun gegen AIDS – ein erreichbares Ziel? MMW Fortschr Med. 2013 Jun 13;155 Suppl 1:36-9. [abstract]

2003 


WILD J, WAGNER R. (2003) Stand und gegenwärtige Strategien der HIV-Vakzineentwicklung. Internist 44:711-718 [abstract]

2002

JASSOY C, WAGNER R. (2002) Perspektiven für die Entwicklung einer HIV Vakzine. Deutsches Ärzteblatt 99:A-1962-1971 [abstract]

2001

WAGNER R. (2001) Neue Impulse für die Biotechnologie durch synthetische Gene. Bioforum 9:610-611

WAGNER R, SCHMIDT, GRAF M, SCHLEEF M. (2001) Optimierte DNA Vakzine und Gentherapievektoren. BioForum 11:824-826

WAGNER R. (2001) Automatisierte Gensynthese als Platfrorm für die entwicklung automatisierter Bioprod. BioForum 7/8: 488

1998

WAGNER R, DEML L. (1998) Fortschritte und Probleme bei der Entwicklung eines HIV-Impfstoffs. in: AIDS und HIV-Infektionen: Diagnostik, Klinik, Behandlung; Handbuch und Atlas für Klinik und Praxis. (H. Jäger Ed.), Ecomed Verlag II-3.5; Seite 1-12

1997

NOTKA F, WAGNER R. (1997) HIV, Chemokine und Rezeptoren: Neue Aspekte zur HIV-Pathogenese. Immunität und Infektion. 105-114

WAGNER R, DEML L. (1997) HIV-Impfstoffentwicklung: Quo vadis? in: AIDS - Neue Perspektiven, therapeutische Erwartungen, die Realität 1997. (H. Jäger ed.) Ecomed Verlag. 6:44-50

1996

WAGNER R, REISCHL U. (1996) Qualitativer und quantitativer  Nukleinsäurenachweis in der molekularen Diagnostik von Infektionskrankheiten. Bedeutung der Virusbelastung bei der HIV Infection. (H. Jäger ed.). Thieme Verlag, 48-59

1995

WAGNER R, REISCHL U. (1995) Neue virologische und immunologische Aspekte der HIV-Infektion. ARZT und Fortbildung. 7:203-209

WAGNER R, MAYER J, WOLF H. (1995). HIV-Pathogenese und Langzeitüberlebende: Auswirkungen auf Therapie und Impfstoffentwicklungen. Deutsche Medizinische Wochenschrift DMW. 120:728-736

WAGNER R, MAYER J, REISCHL U. (1995) Labordiagnostik der HIV-Infektion. Fortschritte der Medizin. 10:39-45

JÄGER H, WAGNER R. (1995) Zur Bedeutung der Virusquantifizierung bei der Behandlung der HIV-Infektion. Deutsches Ärzteblatt. 50:3545-3548

WAGNER R, REISCHL U. (1995) Neue virologische und immunologische Aspekte der HIV-Infektion. in: HIV-Medizin: Möglichkeiten der individualisierten Therapie. Wissenschaftliche Ergebnisse in der Mitte der 90er Jahre. (H. Jäger ed.) Ecomed Verlag. 4:31-40

1994

MAYER J, REISCHL U, WAGNER R. (1994) Labordiagnostik der HIV-Infektion. Labormedizin. 17:12-17

WAGNER R, WOLF H, DEML L. (1994) AIDS, Hepatitis, Tumorviren: Ansätze für die Entwicklung neuartiger Impfstoffe. Blick in die Wissenschaft. 4: 62-72

1993

SCHWARZMANN F, WAGNER R, MAYER J, REISCHL U, WOLF H. (1993) Aktuelle Perspektiven in der molekularen Virologie. Infektion und Immunität. 21:159-164

1992

WAGNER R, WANNER G, FLIEßBACH H, DEBY G, BÖLTZ T, V. BRUNN A, WOLF H. (1992) Entwicklung autologer, chimärer p55/V3 Core Partikel als Modell für eine HIV Vakzine. erschienen in: 100 Jahre Blutserum Therapie 1890-1990. Behring Mitteilungen

Commentaries

2017
Wagner R. (2017) Effective HIV vaccine: narrow path to broadly neutralizing antibodies? Curr Opin HIV AIDS. 2017 Mar 2. [link]

2011
KINDSMÜLLER K, WAGNER R. (2011) Synthetic biology: Impact on the design of innovative vaccines. Hum Vaccin. 2011 Jun 1;7(6):658-62; [abstract]

2009 

MINSHULL J, WAGNER R. (2009) Preventing the misuse of gene synthesis. Nat. Biotechnol. 27(9):800-801; [link]

Meetings

Upcoming Meetings
> more

Jobs

We permanently offer several opportunities for students to conduct research projects in the context of `Forschungs- und Schwerpunktpraktika´.
> more